Develops off-the-shelf engineered natural killer cell therapies for people with autoimmune diseases.
10-K for FY2025, filed Mar 25, 2026
10-Q for Q3 FY2026, filed Nov 5, 2026
−$33.3MView ↗
From cancer to autoimmune disease
The older report described engineered natural killer cell therapies for cancer, including candidates for blood cancers and tumor targets. The latest report focuses on autoimmune diseases and says the oncology studies closed enrollment and were deprioritized.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 25, 2026We are a biopharmaceutical company focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered…View ↗
NKX101 is designed to enhance the power of innate NK cell biology to detect and kill cancerous cells. The primary activating receptor for…View ↗
In addition to our two lead product candidates, we are engaged in extensive discovery and preclinical stage activities directed to…View ↗
Competes with AstraZeneca, Autolus, Bristol-Myers Squibb, Cabaletta, Cartesian, Gilead, iCell, Juventas, JW Therapeutics, Kyverna, Miltenyi, Novartis, Roche, Rui Therapeutics, Synthekine, Adicet, Allogene, Artiva, Atara, and CRISPR Therapeutics
10-K for FY2025, filed Mar 25, 2026A large number of biopharmaceutical companies are applying their technology and development capabilities to the field of B-cell mediated…View ↗
Loading...